Jane Street
SYRE icon

Jane Street’s Spyre Therapeutics SYRE Stock Holding History

Jane Street’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-96,057
Closed -$1.61M – 12350
2025
Q3 		$1.61M Buy
+96,057
New +$1.57M ﹤0.01% 5339
2024
Q4 		– Sell
-20,641
Closed -$607K – 10558
2024
Q3 		$607K Buy
20,641
+9,090
+79% +$253K ﹤0.01% 6851
2024
Q2 		$272K Buy
11,551
+4,341
+60% +$146K ﹤0.01% 7953
2024
Q1 		$273K Buy
+7,210
New +$209K ﹤0.01% 7700
2023
Q3 		– Sell
-2,171
Closed -$24.5K – 9366
2023
Q2 		$24.5K Buy
2,171
+460
+27% +$2.18K ﹤0.01% 8335
2023
Q1 		$12.4K Buy
+1,711
New +$18.8K ﹤0.01% 8717
2020
Q4 		– Sell
-475
Closed -$84K – 8104
2020
Q3 		$84K Sell
475
-24
-5% -$4.44K ﹤0.01% 6799
2020
Q2 		$115K Buy
+499
New +$95K ﹤0.01% 6664

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Jane Street's SYRE Position: Q4 2025 in Review

Jane Street sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 96,057 shares — an estimated $1.61M sold.

Jane Street first reported a position in SYRE in Q2 2020 and held it in 8 quarters. The position peaked at $1.61M in Q3 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Jane Street reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 96,057 Spyre Therapeutics shares in Q4 2025, an estimated $1.61M.
  • Jane Street first reported a position in Spyre Therapeutics in Q2 2020 and held it in 8 quarters.
  • Jane Street's Spyre Therapeutics position peaked at $1.61M in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.